A capable CRO can hit the same particle size, polydispersity, and encapsulation efficiency a strong internal group reaches, so outsourcing formulation screening is rarely a question of whether someone else can do the work. What changes with the decision is where the iteration loop sits, how far your materials travel, and how cost scales with the number of rounds, and each of those depends on where a program is in its life.

Early discovery screening is a tight loop in which each characterized round points to the next lipid or molar ratio and the following round is designed within days, so work that turns over this fast gains the most from staying in one place. Outsourcing fits the cases that fall outside that loop, whether a specialized one-off study that needs a capability the lab does not run, or the move into scale-up and GMP production, where the capacity and quality systems involved are not something a discovery group should own.

The pace of a discovery screen is set by how quickly one round of data turns into the next round of designs. Run in-house, that turnaround can be a day or two, since the same team reads its own characterization data and lays out the next library without anything leaving the building. Sent to a CRO, the same step carries scoping, a materials shipment, time in the provider's queue, and a written report before the next design can even start.

Those added steps are dead time, and they repeat on every round. Across a campaign of ten or fifteen rounds, weeks of calendar time accrue that have nothing to do with the formulation science itself, and in a field where the order in which programs reach the clinic can decide a molecule's commercial life, that is rarely time a team can afford to give away.

An outsourced screen is priced per study, so its cost climbs with every round and climbs fastest in early discovery, exactly when the design is changing most and the round count is highest. The fee covers the provider's instrument, operators, and overhead each time, whether the round is a small ratio sweep or a full library.

In-house screening moves that cost onto reagents and a few hours of operator time on a liquid handler the lab already owns and runs for other assays, so an added round costs little more than the consumables it uses. The more a program iterates, the wider that gap grows, which is why outsourcing suits the occasional specialized study far better than it suits the high-iteration core of a discovery screen.

An outsourced screen is priced per study, so its cost climbs with every round and climbs fastest in early discovery, exactly when the design is changing most and the round count is highest. The fee covers the provider's instrument, operators, and overhead each time, whether the round is a small ratio sweep or a full library.

In-house screening moves that cost onto reagents and a few hours of operator time on a liquid handler the lab already owns and runs for other assays, so an added round costs little more than the consumables it uses. The more a program iterates, the wider that gap grows, which is why outsourcing suits the occasional specialized study far better than it suits the high-iteration core of a discovery screen.

For years, running formulation screening in-house meant buying and maintaining a dedicated microfluidic formulation instrument. A discovery group that could not justify the capital or the bench space had a real reason to send the work out, and that is a large part of why so much LNP screening landed at CROs.

Most screening labs, though, already run an automated liquid handler for reagent preparation and assay setup, and formulation now runs on that same deck. That takes the dedicated instrument out of the decision, so a screen stays inside a workflow the lab already knows, with nothing separate to buy, validate, or house.

The LNP Screening Array brings microfluidic mixing onto standard automated liquid handlers, so the formulation step runs on the deck the lab already uses. Each formulation forms in seconds, and a full round of 100+ formulations runs in one method, with no shipment or queue between a design and its data.

Because the work stays on the deck, scarce material and proprietary compositions never leave the lab, and the full characterization dataset is yours from the first run. Each formulation uses as little as 100 µL with under 50 µL of dead volume, so a program's limited RNA and custom lipids stretch across far more of the screen. Scale-up and GMP can still go to a partner once a lead is ready, while discovery screening stays where it iterates fastest.

Keep discovery screening in-house at 100+ formulations an hour.